Summary

Description (Web site quote)

Aastrom Biosciences, Inc. (NasdaqSC: ASTM) is developing proprietary adult stem cell-based products for the regenerative repair of damaged human tissues and other medical disorders. Aastrom's strategic position in the tissue regeneration and cell therapy sectors is enabled by its proprietary Tissue Repair Cells (TRCs), a mix of bone marrow stem and progenitor cells, and the AastromReplicell® System, an industry-unique automated cell production platform used to produce cells for clinical use. Together TRCs and the AastromReplicell System provide a foundation that the Company is leveraging to produce multiple Prescription Cell Products, the first of which is now in the clinical stage in the U.S. and EU.



TRCs are the core component of the Prescription Cell Products Aastrom is developing for the bone grafting, peripheral vascular disease and cartilage markets. The company also markets the AastromReplicell System and disposable dendritic cell production kits to researchers and institutions developing vaccines to treat cancer and infectious diseases, under its Cell Production Products line.



To date, over 3,000 stem cell production runs have been completed successfully. In multi-center clinical trials involving over 160 patients, TRCs have been demonstrated to be safe and reliable, and to regenerate normal healthy tissues.



Stem cells are human cells that have the capability to form multiple, or in some cases, all types of tissues. Therefore, stem cells represent potentially powerful agents for repairing damaged or diseased tissues.